Author

M. Neuenschwander

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 1

Frequent Co-Authors

J. P. von Kries· 3 shared A. Gohla· 1 shared A. Keller· 1 shared A. Oder· 1 shared A. Schuetz· 1 shared C. Seyffarth· 1 shared C. Villmann· 1 shared C. Zink· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

J. P. von Kries

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4

O. Daumke, S. Mohd, A. Oder, E. Specker, M. Neuenschwander, J. P. von Kries

The paper identifies a drug-like molecule that inhibits EHD4's liposome-stimulated ATPase activity and provides SAR insights for improved inhibitor design.

bioRxiv · Apr 11, 2024Biochemistry

7,8-Dihydroxyflavone is a direct inhibitor of pyridoxal phosphatase

M. Brenner, C. Zink, L. Witzinger, A. Keller, K. Hadamek, S. Bothe, M. Neuenschwander, C. Villmann, J. P. von Kries, H. Schindelin, E. Jeanclos, A. Gohla

This study identifies 7,8-dihydroxyflavone as a direct inhibitor of pyridoxal phosphatase, increasing PLP levels in mouse hippocampal neurons and validating PDXP as a druggable target.

bioRxiv · Oct 4, 2023Biochemistry

An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor

T. Aguirre, G. L. Dornan, S. Hostachy, M. Neuenschwander, C. Seyffarth, V. Haucke, A. Schuetz, J. P. von Kries, D. Fiedler

The paper identifies FMP-201300 as a potent and selective inhibitor for IP6K1 and IP6K2 with a valine gatekeeper mutation, revealing an allosteric mechanism of action.

bioRxiv · Apr 26, 2023Biochemistry